Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD.